Want to see IT:SOL full AI Analyst Report?
SOL Stock Chart & Stats
€53.90
-€0.70(-1.11%)
At close: 4:00 PM EDT
€53.90
-€0.70(-1.11%)
Day’s Range― - ―
52-Week Range€44.85 - €64.00
Previous CloseN/A
Volume24.26K
Average Volume (3M)42.80K
Market Cap
€4.92B
Enterprise Value€4.96K
Total Cash (Recent Filing)€364.71M
Total Debt (Recent Filing)€828.83M
Price to Earnings (P/E)28.5
Beta0.39
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.83%
Share Statistics
EPS (TTM)1.84
Shares Outstanding90,700,000
10 Day Avg. Volume51,713
30 Day Avg. Volume42,799
Financial Highlights & Ratios
PEG Ratio2.06
Price to Book (P/B)3.91
Price to Sales (P/S)2.50
P/FCF Ratio178.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.04
Revenue Forecast (FY)€1.95B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained revenue growth across multiple years indicates continuing demand and market reach rather than reliance on a single temporary boost. This provides a durable foundation for reinvestment, supports operating leverage, and strengthens the company’s ability to compound earnings over the next several quarters.
Stable Operating ProfitabilityStable mid-teens EBIT margins and consistently strong EBITDA margins demonstrate meaningful operating profitability in the specialty chemicals business. This resilience can help fund investment internally and provides a buffer against moderate revenue fluctuations while supporting more predictable earnings generation.
Healthy Returns And Reasonable LeverageConsistently healthy returns on equity indicate that the company has generated solid profitability from its capital base, while historically moderate leverage has limited balance-sheet strain. Together, these characteristics support financial resilience and preserve capacity for ongoing strategic investment.
Bears Say
Declining Free Cash FlowDeclining free cash flow weakens the quality of reported earnings and reduces internally generated funding available for investment, debt reduction, or shareholder returns. If this pressure persists, the company could have less flexibility to absorb operational setbacks or pursue growth without relying more heavily on external financing.
Higher 2025 LeverageThe increase in debt and debt-to-equity during 2025 reduces balance-sheet flexibility even though the overall leverage profile remains reasonable. Higher leverage can raise financing sensitivity and leave fewer options if earnings soften, rates remain elevated, or cash generation stays under pressure.
Gross Margin VolatilityLarge fluctuations at the gross-profit level suggest variability in input costs, pricing, or product mix, creating uncertainty beneath the otherwise stable operating results. Persistent volatility could make earnings less predictable and place pressure on profitability if the company cannot consistently offset cost changes.
SOL SPA News
SOL FAQ
What was SOL SPA’s price range in the past 12 months?
SOL SPA lowest stock price was €44.85 and its highest was €64.00 in the past 12 months.
What is SOL SPA’s market cap?
SOL SPA’s market cap is €4.92B.
When is SOL SPA’s upcoming earnings report date?
SOL SPA’s upcoming earnings report date is Apr 01, 2027 which is in 200 days.
How were SOL SPA’s earnings last quarter?
SOL SPA released its earnings results on Sep 03, 2026. The company reported €0.991 earnings per share for the quarter.
Is SOL SPA overvalued?
According to Wall Street analysts SOL SPA’s price is currently Overvalued.
Does SOL SPA pay dividends?
SOL SPA pays a Annually dividend of €0.45 which represents an annual dividend yield of 0.83%. See more information on SOL SPA dividends here
What is SOL SPA’s EPS estimate?
SOL SPA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SOL SPA have?
SOL SPA has 90,700,000 shares outstanding.
What happened to SOL SPA’s price movement after its last earnings report?
SOL SPA reported an EPS of €0.991 in its last earnings report. Following the earnings report the stock price went up 1.241%.
Which hedge fund is a major shareholder of SOL SPA?
Currently, no hedge funds are holding shares in IT:SOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SOL SPA
SOL S.p.A., a global enterprise established in Monza, Italy, in 1927, operates as a subsidiary of Gas and Technologies World BV. The company primarily focuses on the research, manufacturing, and distribution of a diverse array of technical and medical gases, while simultaneously delivering comprehensive home healthcare solutions and associated medical equipment. Its extensive gas portfolio includes vital elements such as oxygen, nitrogen, and argon, alongside specialized gas mixtures, high-purity gases for the electronics industry, and food-grade gases. These products are supplied to various sectors including chemical, electronics, steel, metal, and food processing, as well as supporting environmental protection, scientific research, and healthcare. In the realm of home healthcare, SOL provides critical in-home therapies like oxygen, mechanical ventilation, and aerosol treatments. It also specializes in the diagnosis and management of respiratory sleep disorders, offers artificial nutrition programs, insulin pump therapy, immunotherapy, and dedicated support for pain and Parkinson's disease. Further extending its healthcare reach, the company delivers general home health and social care services, augmented by telemedicine platforms, digital health tools, and a range of healthcare aids. Beyond these core gas and home healthcare operations, SOL S.p.A. engages in a variety of complementary ventures. These encompass the design, construction, and management of biobanks; the generation and sale of hydroelectric power; and the provision of pre- and post-natal diagnostic screening. The company also develops and markets diagnostic systems and products for research and clinical applications across hospital, environmental, veterinary, and food sectors, alongside specialized bioshipping services for the secure transfer, storage, and handling of biological samples. Additional services include professional training, electromedical equipment support, hospital hygiene, environmental monitoring, and ambulance management, all facilitated by its proprietary InfoHealth SOLution web platform for operational oversight.